Cumberland Pharmaceuticals (CPIX) Cash from Financing Activities (2010 - 2026)
Cumberland Pharmaceuticals (CPIX) posted Cash from Financing Activities of -$763300.0 for Q1 2026, down 11.96% sequentially from -$681738.0 in Q4 2025, and up 86.19% YoY from -$409963.4 in Q1 2025.
Cumberland Pharmaceuticals (CPIX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has reported Cash from Financing Activities for 17 years, with the latest figure at -$763300.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 86.19% year-over-year to -$763300.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.0 million (up 74.42% YoY) and the FY2025 annual result came in at -$6.7 million, down 3525.79% from the prior year.
- Cash from Financing Activities eased to -$763300.0 in Q1 2026 per CPIX's latest filing, from -$681738.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $3.9 million in Q1 2022 and troughed at -$5.5 million in Q1 2025.
- A 5-year average of -$988127.6 and a median of -$882596.0 in 2023 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 401.86% in 2022, down 619.86% in 2022.
- Over 5 years, Cash from Financing Activities stood at -$2.8 million in 2022, then soared by 46.52% to -$1.5 million in 2023, then climbed by 7.31% to -$1.4 million in 2024, then jumped by 50.54% to -$681738.0 in 2025, then declined by 11.96% to -$763300.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$763300.0, -$681738.0, and -$386879.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Cumberland Pharmaceuticals | 116.71 Mn | 112.84 Mn | - | -5.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.39 Mn |
| Jun 30, 2026 | -5.39 Mn |
| Mar 31, 2026 | -763,300.00 |
| Mar 31, 2026 | -763,300.00 |
| Dec 31, 2025 | -681,738.00 |
| Dec 31, 2025 | -681,738.00 |
| Sep 30, 2025 | -386,879.00 |
| Sep 30, 2025 | -386,879.00 |
| Jun 30, 2025 | -150,797.00 |
| Jun 30, 2025 | -150,797.00 |
| Mar 31, 2025 | -5.53 Mn |
| Mar 31, 2025 | -5.53 Mn |
| Dec 31, 2024 | -1.38 Mn |
| Dec 31, 2024 | -1.38 Mn |
| Sep 30, 2024 | -536,836.00 |
| Sep 30, 2024 | -536,836.00 |
| Jun 30, 2024 | -309,575.00 |
| Jun 30, 2024 | -309,575.00 |
| Mar 31, 2024 | 2.42 Mn |
| Mar 31, 2024 | 2.42 Mn |